Changzheng Medical Secures RMB 188.88 Million in Funding to Accelerate ECMO Localization

Source: Securities Daily Network

Our Staff Reporter (Jiao Yue) Recently, the latest transaction results from the Beijing Property Exchange showed that the capital increase project of Aerospace New Long March Medical Instrument (Beijing) Co., Ltd. ("Long March Medical") was successfully completed, with a capital increase of 188.88 million yuan.

This financing round boasts a strong lineup, led by the Beijing Medical and Health Industry Investment Fund (Limited Partnership); with co-investments from Beijing Fengze Zhiyuan Industrial Cultivation Equity Investment Fund Partnership (Limited Partnership), China Aerospace Capital Holdings Co., Ltd., and Gongrong Jintou No. 2 (Beijing) Emerging Industry Equity Investment Fund Partnership (Limited Partnership), forming a diversified and synergistic investment pattern of "policy guidance + industrial empowerment + financial support." At the same time, Aerospace New Long March Medical Instrument (Beijing) Co., Ltd. has implemented an employee stock ownership plan, harnessing the innovative vitality of all employees, injecting lasting momentum into the company’s breakthroughs in key core technologies and solidifying the foundation for China's independent and controllable high-end medical equipment.

Industry data shows that the current financing in the medical device industry is showing obvious structural differentiation, with funds continuing to gather towards top-quality companies and core tracks of China-produced substitution. The requirements for project technical barriers and commercialization capabilities are continuously increasing. Against this backdrop, the fact that Changzheng Medical was able to complete financing at a scale significantly higher than the average level of the same round in the industry during the same period fully demonstrates the market's recognition of its core technical barriers, commercialization capabilities, and broad industrial development space in the high-end medical equipment field.

Public information shows that Aerospace New Long March Medical Instrument (Beijing) Co., Ltd. was established in December 2021, and in 2024 as the "fourNew Industry"Representative, selected into the first batch of Qihang Enterprise List by the State-owned Assets Supervision and Administration Commission of the State Council. Since its establishment, the company has always adhered to "Aerospace TechnologyServing the mission of "Healthy China," Aerospace New Long March Medical Instrument (Beijing) Co., Ltd. applies top-tier servo control, precision manufacturing, and reliability design technologies from the aerospace sector to the research and development of high-end medical equipment. The company utilizes aerospace-grade rigorous standards and cutting-edge technical capabilities in the frontlines of developing critical life support devices. The funds raised from this financing round will be primarily allocated to three core areas: iterative upgrades of key products, clinical trials for critical consumables, and the construction of scaled production capacity alongside market expansion across China. Notably, with the accelerated progress of clinical trials for critical consumables, Aerospace New Long March Medical Instrument is poised to fill the domestic gap in ECMO core consumables produced in China, gradually breaking the long-term market monopoly held by overseas products. This will achieve full-chain self-reliance and controllability from complete equipment to core consumables, strengthening the safety of China's high-end medical equipment and effectively addressing urgent healthcare concerns for the population.

(Editor Zhang Wenling)